AVENGERS #86

Cover shows moderate wear consistent with a mid-grade Bronze Age book: visible spine stress lines and slight whitening along the spine, mild corner blunting at top right and bottom corners, and some minor surface wear/scuffing across the cover art. No major tears, creases, or color breaks are apparent, and the cover retains good color gloss. The book is in a protective sleeve which limits full assessment of edges; interior pages and back cover were not visible and were not assessed.

Avengers #86 (March 1971) arrived during Roy Thomas's long tenure as the title's architect, with Sal Buscema handling penciling chores as the series moved through a run of tightly serialized team adventures. The issue sits just ahead of the celebrated Kree-Skrull War arc that would begin a few issues later and bring Neal Adams's artwork to the title, placing #86 in the workmanlike but well-regarded stretch of early-1970s Avengers storytelling that built the roster dynamics and stakes for that landmark arc. It is not a first appearance or origin issue, but it represents solid mainline continuity from a run collectors track closely.

Market data shows a typical long-run Bronze Age curve: value climbs gently through the mid grades before spiking sharply at the top of the census, with the 9.8 tier commanding roughly ten times the price of a 9.4 copy despite a modest population gap. Demand is concentrated among Avengers run-collectors and Bronze Age specialists rather than character-first-appearance speculators, since the issue's draw is context and completeness rather than a landmark cover or debut. Sales volume across grades 7.0–8.5 is comparatively thin, consistent with a book that circulates steadily but without headline-driven bidding wars.

This is a stable, collectible mid-run issue best suited to buyers assembling a complete Avengers vol. 1 set or filling out the pre-Kree-Skrull War stretch of the title. Raw copies in low and mid grades trade inexpensively and are readily available given the large graded population, while investment-grade interest is essentially limited to true 9.8 submissions, where scarcity relative to demand drives the outsized premium. It is a book for patient set-builders rather than key-issue speculators.